SAN DIEGO, June 14, 2016 /PRNewswire/ --
"As previously stated, we are currently screening several well thought out chemical libraries designed to give us new chemical entities which inhibit and/or activate NR2F6. We are optimistic that this program will identify lead compounds in the next several months and create a new generation of both immune-stimulatory anticancer drugs and immune-inhibitory drugs. The discovery of some molecules that bind to and activate NR2F6 opens significant possibilities in developing an oral drug that suppresses the immune system and can be used to fight autoimmune disorders such as lupus, graft versus host disease, eczema and rheumatoid arthritis," said Harry Lander, Ph.D., President and Chief Scientific Officer of Regen.
Given the difficult nature of the NR2F6 target, Regen is excited that using very stringent parameters, the Company has been able to identify molecules that not only bind and activate it but also have structural properties making them excellent starting points for drug development. Regen is also optimistic the Company will identify inhibitors of NR2F6 in the coming months."
NR2F6 is a molecular switch known as a "orphan nuclear receptor" which controls genes associated with the immune response. Regen has filed numerous patent applications covering means of manipulating NR2F6 in oncology and immunology. Issued US Patent # 9091696 was assigned to Regen and covers means of screening small molecules such as is being done in this program.
"From a patient perspective, development of a 'checkpoint inhibitor pill' offers numerous potential advantages to currently utilized checkpoint inhibitors in terms of cost, lack of need for injections, and potentially better control of the drug's activities," said David Koos, Ph.D., Chairman and CEO of Regen. "And of course developing drugs that stop autoimmune disorders would benefit a large population of patients suffering from these debilitating diseases."
About Regen BioPharma, Inc.
Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP). The company seeks to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space. The company aims to rapidly advance these technologies through pre-clinical and Phase I/II clinical trials. Currently the company is focusing on checkpoint inhibitor and gene silencing therapies for treating cancer, along with developing stem cell treatments for aplastic anemia.
Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
Contact: Regen BioPharma Inc. David R. Koos, PhD Chairman & Chief Executive Officer +1-619-702-1404 Phone +1-619-330-2328 Fax [email protected] The Dorsee Company Debra Dorsee +1-(858)-229-6082 [email protected] http://www.regenbiopharma.com and http://www.regenbiopharmainc.com Twitter: Regen BioPharma News: https://twitter.com/RegenBioPharm
SOURCE Regen BioPharma Inc.
Advertisement
Regen BioPharma, Inc., (OTCQB: RGBP) and (OTCQB: RGBPP) announced today identification of small molecules that activate the Company's newly identified immune checkpoint NR2F6. This is the first of a series of steps in developing small molecules which the Company plans to use as a basis for creating an oral drug that may have potent anti-inflammatory properties. Previously, the Company reported that suppressing NR2F6 leads to immune cell activation, including production of the immune-stimulatory cytokines IL-18, IL-17 and IL-2. Thus, activating NR2F6 will likely lead to immune suppression.
Advertisement
"As previously stated, we are currently screening several well thought out chemical libraries designed to give us new chemical entities which inhibit and/or activate NR2F6. We are optimistic that this program will identify lead compounds in the next several months and create a new generation of both immune-stimulatory anticancer drugs and immune-inhibitory drugs. The discovery of some molecules that bind to and activate NR2F6 opens significant possibilities in developing an oral drug that suppresses the immune system and can be used to fight autoimmune disorders such as lupus, graft versus host disease, eczema and rheumatoid arthritis," said Harry Lander, Ph.D., President and Chief Scientific Officer of Regen.
Given the difficult nature of the NR2F6 target, Regen is excited that using very stringent parameters, the Company has been able to identify molecules that not only bind and activate it but also have structural properties making them excellent starting points for drug development. Regen is also optimistic the Company will identify inhibitors of NR2F6 in the coming months."
NR2F6 is a molecular switch known as a "orphan nuclear receptor" which controls genes associated with the immune response. Regen has filed numerous patent applications covering means of manipulating NR2F6 in oncology and immunology. Issued US Patent # 9091696 was assigned to Regen and covers means of screening small molecules such as is being done in this program.
"From a patient perspective, development of a 'checkpoint inhibitor pill' offers numerous potential advantages to currently utilized checkpoint inhibitors in terms of cost, lack of need for injections, and potentially better control of the drug's activities," said David Koos, Ph.D., Chairman and CEO of Regen. "And of course developing drugs that stop autoimmune disorders would benefit a large population of patients suffering from these debilitating diseases."
About Regen BioPharma, Inc.
Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP). The company seeks to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space. The company aims to rapidly advance these technologies through pre-clinical and Phase I/II clinical trials. Currently the company is focusing on checkpoint inhibitor and gene silencing therapies for treating cancer, along with developing stem cell treatments for aplastic anemia.
Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
Contact: Regen BioPharma Inc. David R. Koos, PhD Chairman & Chief Executive Officer +1-619-702-1404 Phone +1-619-330-2328 Fax [email protected] The Dorsee Company Debra Dorsee +1-(858)-229-6082 [email protected] http://www.regenbiopharma.com and http://www.regenbiopharmainc.com Twitter: Regen BioPharma News: https://twitter.com/RegenBioPharm
SOURCE Regen BioPharma Inc.
